Cantor Fitzgerald Downgrades ADMA Biologics Inc. (ADMA) to Neutral From Overweight

ADMA Biologics Inc. (NASDAQ:ADMA) is one of the most undervalued biotech stocks to buy right now. Cantor Fitzgerald downgraded ADMA Biologics Inc. (NASDAQ:ADMA) to Neutral from Overweight on March 26, without assigning a price target. The firm stated that it spoke with a number of investors after a short report’s claim that ADMA Biologics Inc. (NASDAQ:ADMA) is boosting Asceniv revenues through channel stuffing, and stated that investors are disappointed over the company’s response and lack of direct communication after the report. The firm further contended that although the company put out a statement, they were “hoping to have more specific feedback addressing the direct claims in the report”. The firm also cited the lack of clarity and concerns associated with the increased days’ sales outstanding and accounts receivable for the downgrade.

ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios

ADMA Biologics Inc. (NASDAQ:ADMA) issued a statement refuting the allegations by Culper Research on March 27, calling them “unsubstantiated, misleading, and inaccurate”. The company did so to “alleviate confusion in the marketplace” regarding the company’s operations and business practices.

ADMA Biologics Inc. (NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics. Its operations are divided into the following business segments: ADMA BioManufacturing and Plasma Collection Center.

While we acknowledge the risk and potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ADMA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.